



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

24 Feb 2020 (#9)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notice

- **Epidemic Preparedness: COVID-19**, funded by partnership between Wellcome Trust and the UK Department for International Development (DFID) through the Joint Initiative on Research in Epidemic Preparedness and Response, aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity. Submit expressions of interest as soon as possible. **Level of funding:** Up to £2 million. **Duration of funding:** Up to 2 years. You must send your expression of interest as soon as possible to [epidemics@wellcome.ac.uk](mailto:epidemics@wellcome.ac.uk). Include a brief outline of your proposal including information about the lead applicant, team members and collaborators (500 words maximum). Wellcome trust contact you within two working days of receiving your email. If suitable, we'll invite you to submit an application.
- Notice of Intent to Publish a Funding Opportunity Announcement for **Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research** from National Cancer Institute, National Institute of Environmental Health Sciences, NIH Office of Research on Women's Health and Fogarty: [GEOHealth Hubs Research U01 \(NOT-TW-20-002\)](#); [GEOHealth Hubs Research Training U2R \(NOT-TW-20-003\)](#). Learn more about Fogarty's [Global Environmental and Occupational Health \(GEOHealth\)](#) program. Estimated publication date of funding opportunity announcement: July 1, 2020. First estimated application due date: November 4, 2020
- NIAID received a 6.6 % increase for FY 2020, which includes an additional \$50 million to combat antimicrobial resistance and \$60 million to develop universal influenza vaccines. Good news! [NIAID adjusted paylines](#) for R01s, R03s, and R21s.
  - Research Projects (R01) for established investigators: 14 percentile
  - Research Projects (R01) for new and early-stage investigators: 18 percentile
  - Small Grants (R03): 31 overall impact score
  - Exploratory/Developmental Grants (R21): 31 overall impact score
- NIAID intends to establish CARB Interdisciplinary Research Units (CARBIRUs) to bring together investigators from diverse disciplines and coordinate activities that address key research gaps in the field of antibacterial resistance. If you are a researcher or clinician whose research is in microbiology, immunology, or other related fields, consider applying to the new funding opportunity announcement (FOA) [Combating Antibiotic-Resistant Bacteria \(CARB\) Interdisciplinary Research Units \(U19, Clinical Trial Not Allowed\)](#)
- [Dr. Dimitrios Vatakis](#) and [Dr. Shiv Prasad](#), both scientific review officers from NIH's Center for Scientific Review, will present on peer review of HIV/AIDS grant applications as part of the [Conference on Retroviruses and Opportunistic Infections 2020](#) meeting. The session will take place on Sunday, March 8 at 8:00 a.m. Eastern Time, just before the Program Committee Workshop for New Investigators and Trainees. Drs. Vatakis and Prasad will describe the grant application review process with new and early-stage investigators in mind, focusing on topics peer reviewers assess and how applicants can best provide reviewers the information they need.

### 1. Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (U19 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-001](#)

**Type:** U19

**Application Due Date:** May 8, 2020 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications to establish Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (CARBIRUs) focused on improving our understanding of bacterial and host factors important for antibacterial resistance and infection to inform development of new approaches to prevent, diagnose, and treat antibacterial-resistant infections.

**Budget:** NIAID intends to commit \$10 million in FY 2021 to fund 5-6 awards. Application budgets are limited to up to \$1.5 million direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 2. Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-FD-20-027](#)

**Type:** R01

**Application Due Date:** April 22, 2020 by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** Center for Biologics Evaluation and Research (CBER), FDA seeks to support the development of innovative pathogen reduction technologies for whole blood and blood components to prevent transfusion-transmitted infectious diseases.

**Budget:** CBER intends to fund up to \$8,000,000, for fiscal year 2020 in support of this grant program. For fiscal year 2020 it is anticipated that up to (5) awards will be made, not to exceed \$8,000,000 in total costs (direct plus indirect). Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): YR 01: \$1,600,000 and YR 02: \$1,600,000. The maximum project period is 2 years.

### 3. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-FD-21-001](#)

**Type:** R01

**Application Due Date:** October 6, 2020, October 5, 2021; by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to fund well-controlled studies in support of a new indication or change in labeling of products to address unmet needs in rare diseases or conditions. Through the funding of efficient and innovative clinical studies evaluating safety and/or efficacy, FDA expects to increase the number of treatments for rare diseases with an unmet medical need and exert a broad and positive impact on rare disease drug development.

**Budget:** Award(s) will provide one (1) year of support and include future recommended support for additional three (3) years contingent upon annual appropriations, availability of funding and satisfactory awardee performance. Applicants requesting \$500,000 or more in direct costs in any year (independent of the optional Innovative Demonstration Project) must provide a letter of request (separate from the Letter of Intent) to the Scientific/ Research Contact at least 4 weeks prior to the application deadline. Consortium/contractual facilities and administrative (F&A) costs do not count against the direct cost limit. For the optional Innovative Demonstration Project Funding, the maximum amount requested shall not exceed \$500,000 total costs per year. The maximum project period is four (4) years, however, the length of support will depend on the nature of the study. For those studies with an expected duration of more than 1 year, a second, third, or fourth year of non-competitive continuation of support will depend on the following factors: (1) Performance during the preceding year; (2) compliance with regulatory requirements of IND/investigational device exemption (IDE), if applicable; and (3) availability of Federal funds.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105